CN115820542A - 一种cho细胞无血清传代培养基及其制备方法和应用 - Google Patents
一种cho细胞无血清传代培养基及其制备方法和应用 Download PDFInfo
- Publication number
- CN115820542A CN115820542A CN202310025615.9A CN202310025615A CN115820542A CN 115820542 A CN115820542 A CN 115820542A CN 202310025615 A CN202310025615 A CN 202310025615A CN 115820542 A CN115820542 A CN 115820542A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- cho
- serum
- sfm
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004978 chinese hamster ovary cell Anatomy 0.000 title claims abstract description 19
- 239000012879 subculture medium Substances 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title description 5
- 210000004027 cell Anatomy 0.000 claims abstract description 50
- 229940088594 vitamin Drugs 0.000 claims abstract description 32
- 229930003231 vitamin Natural products 0.000 claims abstract description 32
- 235000013343 vitamin Nutrition 0.000 claims abstract description 32
- 239000011782 vitamin Substances 0.000 claims abstract description 32
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 29
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 16
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims abstract description 12
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims abstract description 12
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims abstract description 12
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims abstract description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 11
- 239000000654 additive Substances 0.000 claims abstract description 11
- 235000013619 trace mineral Nutrition 0.000 claims abstract description 11
- 239000011573 trace mineral Substances 0.000 claims abstract description 11
- 102000004877 Insulin Human genes 0.000 claims abstract description 8
- 108090001061 Insulin Proteins 0.000 claims abstract description 8
- 102000004338 Transferrin Human genes 0.000 claims abstract description 8
- 108090000901 Transferrin Proteins 0.000 claims abstract description 8
- 229940125396 insulin Drugs 0.000 claims abstract description 8
- 239000012581 transferrin Substances 0.000 claims abstract description 8
- 108010088751 Albumins Proteins 0.000 claims abstract description 7
- 102000009027 Albumins Human genes 0.000 claims abstract description 7
- 229910017053 inorganic salt Inorganic materials 0.000 claims abstract description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 6
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 150000001413 amino acids Chemical class 0.000 claims abstract description 6
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229920003045 dextran sodium sulfate Polymers 0.000 claims abstract description 6
- 239000008103 glucose Substances 0.000 claims abstract description 6
- 229940054269 sodium pyruvate Drugs 0.000 claims abstract description 6
- 229940063675 spermine Drugs 0.000 claims abstract description 6
- 150000002632 lipids Chemical class 0.000 claims abstract description 3
- 239000000306 component Substances 0.000 claims description 15
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 12
- 239000000413 hydrolysate Substances 0.000 claims description 11
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 10
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 10
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 10
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 10
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 10
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 10
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 8
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 244000068988 Glycine max Species 0.000 claims description 6
- 235000010469 Glycine max Nutrition 0.000 claims description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 6
- 239000001888 Peptone Substances 0.000 claims description 6
- 108010080698 Peptones Proteins 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 229960000304 folic acid Drugs 0.000 claims description 6
- 235000019152 folic acid Nutrition 0.000 claims description 6
- 239000011724 folic acid Substances 0.000 claims description 6
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims description 6
- 235000019136 lipoic acid Nutrition 0.000 claims description 6
- 235000019319 peptone Nutrition 0.000 claims description 6
- 229960002663 thioctic acid Drugs 0.000 claims description 6
- CMXXUDSWGMGYLZ-XRIGFGBMSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride;hydrate Chemical compound O.Cl.OC(=O)[C@@H](N)CC1=CN=CN1 CMXXUDSWGMGYLZ-XRIGFGBMSA-N 0.000 claims description 5
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 claims description 5
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 5
- 235000019743 Choline chloride Nutrition 0.000 claims description 5
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 5
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 5
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 5
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 5
- 235000019393 L-cystine Nutrition 0.000 claims description 5
- 239000004158 L-cystine Substances 0.000 claims description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 5
- 229930182844 L-isoleucine Natural products 0.000 claims description 5
- 239000004395 L-leucine Substances 0.000 claims description 5
- 235000019454 L-leucine Nutrition 0.000 claims description 5
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 5
- 229930195722 L-methionine Natural products 0.000 claims description 5
- 229930182821 L-proline Natural products 0.000 claims description 5
- 239000004473 Threonine Substances 0.000 claims description 5
- 229940024606 amino acid Drugs 0.000 claims description 5
- 235000001014 amino acid Nutrition 0.000 claims description 5
- 229960001230 asparagine Drugs 0.000 claims description 5
- 229960005261 aspartic acid Drugs 0.000 claims description 5
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 5
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 claims description 5
- 229940052299 calcium chloride dihydrate Drugs 0.000 claims description 5
- 229960003178 choline chloride Drugs 0.000 claims description 5
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 5
- 229960003067 cystine Drugs 0.000 claims description 5
- WFTCFVUQORELJZ-USHJOAKVSA-L disodium;(2s)-2-amino-3-(4-oxidophenyl)propanoate;dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)[C@@H](N)CC1=CC=C([O-])C=C1 WFTCFVUQORELJZ-USHJOAKVSA-L 0.000 claims description 5
- 229960002989 glutamic acid Drugs 0.000 claims description 5
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 5
- SZQUEWJRBJDHSM-UHFFFAOYSA-N iron(3+);trinitrate;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O SZQUEWJRBJDHSM-UHFFFAOYSA-N 0.000 claims description 5
- 229960000310 isoleucine Drugs 0.000 claims description 5
- 229960003136 leucine Drugs 0.000 claims description 5
- 229960004452 methionine Drugs 0.000 claims description 5
- 229960003966 nicotinamide Drugs 0.000 claims description 5
- 235000005152 nicotinamide Nutrition 0.000 claims description 5
- 239000011570 nicotinamide Substances 0.000 claims description 5
- 229960002429 proline Drugs 0.000 claims description 5
- LJPYJRMMPVFEKR-UHFFFAOYSA-N prop-2-ynylurea Chemical compound NC(=O)NCC#C LJPYJRMMPVFEKR-UHFFFAOYSA-N 0.000 claims description 5
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 5
- 229960001153 serine Drugs 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229960002898 threonine Drugs 0.000 claims description 5
- 229960004295 valine Drugs 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 230000006229 amino acid addition Effects 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- YBMRDBCBODYGJE-UHFFFAOYSA-N germanium dioxide Chemical compound O=[Ge]=O YBMRDBCBODYGJE-UHFFFAOYSA-N 0.000 claims description 4
- 229960005190 phenylalanine Drugs 0.000 claims description 4
- 229960004799 tryptophan Drugs 0.000 claims description 4
- 229940089133 vitamin b6 5 mg Drugs 0.000 claims description 4
- 229910005793 GeO 2 Inorganic materials 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 claims description 2
- 238000011146 sterile filtration Methods 0.000 claims description 2
- 229940047044 vitamin b 12 5 mg Drugs 0.000 claims description 2
- 239000006143 cell culture medium Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 abstract description 8
- 230000003833 cell viability Effects 0.000 abstract description 6
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 abstract description 2
- -1 P-188 Chemical compound 0.000 abstract 1
- 108010009736 Protein Hydrolysates Proteins 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- 229940031098 ethanolamine Drugs 0.000 abstract 1
- 229960001031 glucose Drugs 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 239000002609 medium Substances 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 9
- 230000012010 growth Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000010413 mother solution Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229940086392 calcium pantothenate 7 mg Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940087401 inositol 150 mg Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一种CHO细胞无血清传代培养基,所述无血清传代培养基包括氨基酸、维生素、脂质、无机盐、能量、微量元素以及其他添加物;其中,所述其他添加物包括胰岛素、转铁蛋白、白蛋白、酵母水解物、大豆蛋白胨、乙醇胺、精胺、葡萄糖、丙酮酸钠、P‑188、硫酸葡聚糖钠盐和次黄嘌呤。本发明的培养基能够促进细胞正常倍增,维持细胞活率,确保细胞能够长期传代。
Description
技术领域
本发明涉及一种适用于CHO细胞无血清传代培养基,属于CHO-K1细胞培养领域。
背景技术
CHO细胞,即中国仓鼠卵巢细胞(Chinese hamster ovary cells),属于成纤维细胞,具有不死性,可以传至百代,是生物技术药物中的的表达宿主,适用于工业大规模化生产。而在大规模生产前,需要对种子细胞进行传代扩增,确保细胞倍增正常,状态良好,以便于放大生产过程中细胞本身不会出现问题。培养其优势在于,表达的糖基化蛋白在分子结构和生物学功能方面是最接近天然分子蛋白;几乎无内源蛋白分泌,表达产物分泌到胞外,利于纯化。目前,CHO细胞已成为生物技术药物最为重要的表达或生产系统,成为了基因工程和生物制药的重要工具。
目前传统的CHO细胞培养方式是在含有血清的培养基中生长,血清给细胞提供生长增殖所需的激素、生长因子、转移蛋白和其他营养物质,由于所含成分复杂,且不同产地、批次间差异较大,因而给动物细胞大规模培养工艺造成了许多不利因素。因此,无血清培养基已成为哺乳动物细胞培养技术的发展方向。
发明内容
发明目的:为解决目前技术中存在的一些问题,本发明提供一种适用于CHO-K1细胞,在CHO细胞中,K1运用广泛,被人们用于大量研究实验。无血清传代培养基的制备方法,确保细胞在扩增传代过程中倍增正常,状态良好。
为了解决上述技术问题,本发明公开了一种CHO细胞无血清传代培养基,所述无血清传代培养基包括氨基酸、维生素、脂质、无机盐、能量、微量元素以及其他添加物;其中:
氨基酸添加浓度范围为:L-精氨酸盐酸盐300-700mg/L、L-天冬酰胺500-800mg L、L-天冬氨酸200-500mg/L、L-半胱氨酸盐酸盐一水合物100-300mg/L、L-谷氨酸200-350mg/L、L-组氨酸盐酸盐一水合物200-350mg/L、L-异亮氨酸300-450mg/L、L-亮氨酸500-800mg/L、L-蛋氨酸100-250mg/L、L-赖氨酸盐酸盐400-550mg/L、L-脯氨酸300-600mg/L、L-缬氨酸350-550mg/L、L-苯丙氨酸150-400mg/L、L-苏氨酸200-550mg/L、L-色氨酸200-400mg/L、L-胱氨酸100-200mg/L、L-丝氨酸500-900mg/L和L-酪氨酸二钠盐二水合物100-340mg/L;
维生素添加浓度范围为:维生素B2 1-2mg/L、维生素H1-5mg/L、叶酸1-10mg/L、硫辛酸0.2-3mg/L、维生素B12 1-8mg/L、i-肌醇50-200mg/L、维生素B6 1-5mg/L、维生素B1 4-10mg/L、维生素C10-30mg/L、D-泛酸钙5-20mg/L、烟酰胺1-10mg/L、氯化胆碱50-100mg/L;
无机盐及微量元素添加浓度范围为:MgSO4·7H2O 50-100mg/L、KCl 500-1000mg/L、硝酸铁九水合物0.1-0.5mg/L、二水氯化钙200-300mg/L、NaH2PO4 100-700mg/L、NaHCO31800-2500mg/L、ZnSO4 2-5mg/L、AlCl3·6H2O 0.0001-0.0005mg/L、NaVO3
0.001-0.005mg/L、Na2SeO3 0.007-0.020mg/L、CuSO4·5H2O 0.002-0.005mg/L、NaF0.001-0.006mg/L、GeO2 0.002-0.005mg/L;
其他添加物的添加浓度范围为:胰岛素5-30mg/L、转铁蛋白5-30mg/L、白蛋白5-30mg/L、酵母水解物2000-7000mg/L或大豆蛋白胨3000-6000mg/L、乙醇胺2.5-15mg/L、精胺1-5mg/L、葡萄糖2000-6500mg/L、丙酮酸钠2000-6500mg/L、P-188 1000-2500mg/L、硫酸葡聚糖钠盐1000-3000mg/L和次黄嘌呤0.5-2mg/L。
在一个优选的实施方式中,所述无血清传代培养基成分包含如下组成:
氨基酸添加浓度范围为:L-精氨酸盐酸盐400-600mg/L、L-天冬酰胺600-800mg L、L-天冬氨酸300-400mg/L、L-半胱氨酸盐酸盐一水合物200-300mg/L、L-谷氨酸300-350mg/L、L-组氨酸盐酸盐一水合物200-300mg/L、L-异亮氨酸300-400mg/L、L-亮氨酸500-600mg/L、L-蛋氨酸150-200mg/L、L-赖氨酸盐酸盐450-500mg/L、L-脯氨酸300-400mg/L、L-缬氨酸350-500mg/L、L-苯丙氨酸200-300mg/L、L-苏氨酸250-350mg/L、L-色氨酸200-300mg/L、L-胱氨酸100-200mg/L、L-丝氨酸700-900mg/L和L-酪氨酸二钠盐二水合物250-300mg/L;
维生素添加浓度范围为:维生素B2 1-2mg/L、维生素H 2-5mg/L、叶酸1-6mg/L、硫辛酸0.2-1mg/L、维生素B12 1-5mg/L、i-肌醇80-150mg/L、维生素B6 2-5mg/L、维生素B1 2-8mg/L、维生素C10-20mg/L、D-泛酸钙5-15mg/L、烟酰胺5-10mg/L、氯化胆碱50-100mg/L;
无机盐及微量元素添加浓度范围为:MgSO4·7H2O 50-100mg/L、KCl 500-1000mg/L、硝酸铁九水合物0.1-0.5mg/L、二水氯化钙200-300mg/L、NaH2PO4 100-700mg/L、NaHCO31800-2500mg/L、ZnSO4 2-5mg/L、AlCl3·6H2O 0.0001-0.0005mg/L、NaVO3
0.001-0.005mg/L、Na2SeO3 0.007-0.020mg/L、CuSO4·5H2O 0.002-0.005mg/L、NaF0.001-0.006mg/L、GeO2 0.002-0.005mg/L;
其他添加物的添加浓度范围为:胰岛素10-20mg/L、转铁蛋白10-20mg/L、白蛋白15-30mg/L、酵母水解物2000-5000mg/L或大豆蛋白胨3000-5000mg/L、乙醇胺2.5-15mg/L、精胺1-5mg/L、葡萄糖5000-6500mg/L、丙酮酸钠2000-6500mg/L、P-1881000-2500mg/L、硫酸葡聚糖钠盐1000-3000mg/L、次黄嘌呤0.5-2mg/L。
本发明进一步提供了上述适用于CHO细胞无血清传代培养基的配置方法,其特征在于,按体积分别称量对应组分的克数溶解后,调节pH在7.0±0.2,加水定容后,使用氯化钠调节渗透压280±10mOsm/kg,后使用0.22微摩尔滤膜无菌过滤,即得所述适用于CHO-K1细胞无血清传代培养基。
本发明还提出了上述适用于CHO细胞无血清传代培养基在CHO细胞培养中的用途,优选地,所述CHO细胞为CHO-K1。
现在大多数培养基中使用血清的添加来确保细胞的生长,而血清中有大量不稳定成分,批次间差异大,容易对培养造成污染,本发明通过一些血清替代物,蛋白,水解物的添加,减少了污染的风险,降低培养成本。
有益效果:本发明通过使用糖类、氨基酸、维生素、无机盐、微量元素、促进生长的因子等配置无血清传代培养基,并额外添加水解物,促进细胞正常倍增,维持细胞活率,确保细胞能够长期传代。
附图说明
图1为CHO-K1细胞在传代培养中使用本发明培养基SFM1-4和对比培养基的活细胞密度随时间变化图;
图2为CHO-K1细胞传代培养中使用本发明培养基SFM1-4和对比培养基的活率随时间变化图;
图3为CHO-K1细胞传代培养中使用本发明培养基SFM1-4和对比培养基的直径随时间变化;
图4为CHO-K1细胞在Batch培养中使用本发明培养基SFM1-4和对比培养基的活细胞密度随时间变化图;
图5为CHO-K1细胞在Batch培养中使用本发明培养基SFM1-4和对比培养基的活率随时间变化图;
图6为CHO-K1细胞在Batch培养中使用本发明培养基SFM1-4和对比培养基的直径随时间变化图。
具体实施方式
下面通过具体的实施例详细说明本发明。
实施例1
本实施例所描述的适用于CHO-K1无血清培养基包含以下组分:氨基酸、维生素、无机盐、微量元素以及其他添加物质。
其中:
氨基酸浓度含量如下:
L-精氨酸盐酸盐350mg/L、L-天冬酰胺500mg/L、L-天冬氨酸250mg/L、L-半胱氨酸盐酸盐一水合物150mg/L、L-谷氨酸350mg/L、L-组氨酸盐酸盐一水合物320mg/L、L-异亮氨酸300mg/L、L-亮氨酸650mg/L、L-蛋氨酸100mg/L、L-赖氨酸盐酸盐400mg/L、L-脯氨酸300mg/L、L-缬氨酸380mg/L、L-苯丙氨酸250mg/L、L-苏氨酸280mg/L、L-色氨酸250mg/L、L-胱氨酸150mg/L、L-丝氨酸870mg/L、L-酪氨酸二钠盐二水合物290mg/L;
维生素浓度含量如下:
维生素B2 1.4mg/L、维生素H1mg/L、叶酸1.5mg/L、硫辛酸0.5mg/L、维生素B122mg/L、i-肌醇150mg/L、维生素B6 4mg/L、维生素B1 4mg/L、维生素C15mg/L、D-泛酸钙7mg/L、烟酰胺15mg/L、氯化胆碱60mg/L;
无机盐及微量元素浓度含量如下:
MgSO4·7H2O 75mg/L、KCl 550mg/L、硝酸铁九水合物0.1mg/L、二水氯化钙275mg/L、NaH2PO4 210mg/L、NaHCO3 2000mg/L、ZnSO4 2.5mg/L、AlCl3·6H2O 0.0002mg/L、NaVO30.003mg/L、Na2SeO3 0.01mg/L、CuSO4·5H2O 0.005mg/L、NaF 0.004mg/L、GeO2
0.005mg/L;
其他物质添加浓度含量如下:
胰岛素10mg/L、转铁蛋白10mg/L、白蛋白15mg/L、乙醇胺2.5mg/L、精胺2mg/L、葡萄糖6000mg/L、丙酮酸钠6500mg/L、P-188 2000mg/L、硫酸葡聚糖钠盐2500mg/L、次黄嘌呤1mg/L、酵母水解物的浓度为2500mg/L。
本实施例制备的培养基命名为SFM-1,具体配置方法如下:
(1)维生素H、维生素B2、叶酸、硫辛酸在碱性溶液(NaOH溶液中)中溶解;
(2)把所有微量元素配置成母液D1,溶剂为水;
(3)胰岛素、转铁蛋白使用PBS溶解,其中胰岛素需要在pH 2-3中溶解,转铁蛋白在正常的PBS溶液中溶解,不需要另外调整PH,分别配置成母液浓度为10mg/ml D2、10mg/mlD3,白蛋白在水中直接溶解配成母液浓度为15mg/ml的D4;
(4)称量其他组分在注射水中逐一溶解;
(5)将母液D1、D2、D3、D4,按照所需浓度加入到步骤4中,搅拌5min;
(6)调节溶液pH,确保范围在7.0±0.2后定容;
(7)使用NaCl调节渗透压范围在280±10mOsm/kg。
实施例2
将实施例1的酵母水解物的浓度添加改为5000mg/L,其他按照实施例1配置,浓度成分不变,命名为SFM-2。
实施例3
将案例1的酵母水解物添加物改为大豆蛋白胨3000mg/L,其他按照案例1配置,浓度成分不变,命名为SFM-3。
实施例4
将案例1的酵母水解物添加物改为大豆蛋白胨5000mg/L,其他按照案例1配置,浓度成分不变,命名为SFM-4。
对比例对比培养基为Gibco公司CD CHO培养基,CD CHO是Gibco公司推出的专门适用于培养CHO-K1等细胞系的商业化传代培养基。
CD CHO培养使用的细胞株与本发明实验中的细胞株为同一株,均为CHO-K1,同时传代培养23天,SFM-1、SFM-2、SFM-3、SFM-4、CD CHO为同一批次试验。细胞密度单位106Cells/m,细胞活率单位%,细胞直径单位mm。
表1和图1为SFM-1、SFM-2、SFM-3、SFM-4和CD CHO培养基传代过程中活细胞密度数据,传代当天的计数以及传代一定天数后的计数结果,本发明所使用的四种案例均能使细胞正常生长,且生长密度与CD CHO基本一致。
表1
实验操作 | 传代天数 | SFM-1 | SFM-2 | SFM-3 | SFM-4 | CD CHO |
传代 | 0 | 0.48 | 0.51 | 0.46 | 0.40 | 0.50 |
计数 | 2 | 3.17 | 3.00 | 2.56 | 2.93 | 2.55 |
传代 | 2 | 0.32 | 0.36 | 0.37 | 0.51 | 0.50 |
计数 | 4 | 1.99 | 1.95 | 1.91 | 2.55 | 2.04 |
传代 | 4 | 0.45 | 0.50 | 0.51 | 0.51 | 0.5 |
计数 | 6 | 2.43 | 3.02 | 2.23 | 3.28 | 2.29 |
传代 | 6 | 0.57 | 0.61 | 0.58 | 0.42 | 0.5 |
计数 | 8 | 2.75 | 3.52 | 2.5 | 2.98 | 1.92 |
传代 | 8 | 1.12 | 0.9 | 1.14 | 1.02 | 1 |
计数 | 9 | 2.15 | 2.17 | 2.31 | 2.59 | 2.15 |
传代 | 9 | 0.33 | 0.32 | 0.4 | 0.29 | 0.32 |
计数 | 12 | 2.68 | 3.48 | 3 | 3.81 | 3.38 |
传代 | 12 | 0.47 | 0.5 | 0.62 | 0.52 | 0.4 |
计数 | 14 | 2.07 | 2.33 | 2.83 | 2.63 | 2.51 |
传代 | 14 | 0.51 | 0.49 | 0.65 | 0.49 | 0.5 |
计数 | 16 | 2.63 | 2.56 | 3.5 | 2.8 | 2.38 |
传代 | 16 | 0.28 | 0.26 | 0.29 | 0.35 | 0.3 |
计数 | 19 | 2.02 | 1.56 | 2.89 | 3.74 | 3.88 |
传代 | 19 | 0.57 | 0.56 | 0.58 | 0.52 | 0.5 |
计数 | 21 | 2.3 | 1.72 | 3.38 | 3.51 | 2.27 |
传代 | 21 | 0.51 | 0.56 | 0.51 | 0.49 | 0.5 |
计数 | 23 | 2.07 | 2.48 | 2.57 | 2.69 | 2.4 |
表2为SFM-1、SFM-2、SFM-3、SFM-4和CD CHO培养基平均倍增时间对比数据,由数据可以看出:本发明的所有组合均能使得细胞在24h内倍增一次,不管是酵母水解物还是大豆蛋白胨,随着浓度增加,细胞生长的越快,倍增时间越短,本发明所有组合均比CD CHO倍增时间短,细胞生长快。
表2
培养基 | 平均倍增时间 |
SFM-1 | 21.96h |
SFM-2 | 21.57h |
SFM-3 | 21.46h |
SFM-4 | 18.82h |
CD CHO | 21.42h |
表3和图2为SFM-1、SFM-2、SFM-3和CD CHO培养基传代过程中细胞活率数据。表中数据可以得出:本发明四组组合在传代过程中细胞活率均在95%以上,细胞状态良好,与对比CD CHO培养基保持一致。
表3
表4和图3为SFM-1、SFM-2、SFM-3、SFM-4和CD CHO培养基传代过程中细胞直径数,根据数据对比发现:本发明四组组合在传代过程中,细胞直径与CD CHO基本保持一致,在14-15mm之间,符合细胞传代生长过程中正常指标。
表4
表5和图4为SFM-1、SFM-2、SFM-3、SFM-4和CD CHO培养基在Batch培养中活细胞密度对比数据,由下面数据可以得出:本发明实验组细胞倍增正常,且最高生长密度(PCVD)在D5或者D6达到最高,与CD CHO保持一致,其最高密度都是比CD CHO高,D7后密度下降,符合细胞四个周期和生长曲线,所有组合的细胞最高密度均比对照组CD CHO高,其中,SFM-4最高,与传代结果呼应。
表5
VCD(10<sup>6</sup>) | D0 | D3 | D4 | D5 | D6 | D7 |
SFM-1 | 0.48 | 4.00 | 8.11 | 13.40 | 13.30 | 12.50 |
SFM-2 | 0.50 | 4.00 | 7.17 | 12.6 | 15.7 | 7.04 |
SFM-3 | 0.45 | 4.50 | 8.6 | 15.8 | 16.1 | 9.02 |
SFM-4 | 0.50 | 5.91 | 9.26 | 16.20 | 17.40 | 7.81 |
CD CHO | 0.60 | 6.84 | 10.4 | 11.9 | 9.99 | 9.02 |
表6和图5为SFM-1、SFM-2、SFM-3、SFM-4和CD CHO培养基在Batch培养中细胞活率对比数据,有数据可知:所有组合的细胞活率均在正常范围内,D7后活率骤降,也符合细胞生长曲线,其中,CD CHO在D7的时候活率较高,是由于其最高密度较其他低,培养基中营养物质未消耗完全。
表6
细胞活率(%) | D0 | D3 | D4 | D5 | D6 | D7 |
SFM-1 | 96.83 | 98.89 | 98.76 | 97.69 | 88.23 | 63.52 |
SFM-2 | 97.98 | 98.88 | 99.22 | 98.84 | 96.87 | 49.08 |
SFM-3 | 97.57 | 99.91 | 99.22 | 97.06 | 92.89 | 73.19 |
SFM-4 | 96.83 | 98.89 | 98.76 | 97.69 | 88.23 | 63.52 |
CD CHO | 99.40 | 98.50 | 99.15 | 98.10 | 96.96 | 89.24 |
表7和图6为SFM-1、SFM-2、SFM-3、SFM-4和CD CHO培养基在Batch培养中细胞直径对比数据,根据数据可知:D0-D6期间,所有培养组合细胞与CD CHO直径均在14-15mm之间,说明培养基中营养成分齐全,与传代时的直径也保持了一致,D6后随着细胞的活率,密度下降,细胞直径开始变小,符合细胞生长规律。
Dia | D0 | D3 | D4 | D5 | D6 | D7 |
SFM-1 | 14.73 | 15.07 | 14.72 | 14.40 | 13.41 | 12.08 |
SFM-2 | 14.69 | 14.88 | 14.76 | 14.68 | 14.34 | 12.88 |
SFM-3 | 14.95 | 14.95 | 14.73 | 14.76 | 13.34 | 12.99 |
SFM-4 | 14.58 | 14.65 | 14.25 | 14.26 | 14.21 | 12.25 |
CD CHO | 14.49 | 14.78 | 14.47 | 14.38 | 13.23 | 12.52 |
本发明提供了一种用于CHO-K1细胞无血清传代培养基的制备方法的思路及方法,具体实现该技术方案的方法和途径很多,以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。本实施例中未明确的各组成部分均可用现有技术加以实现。
Claims (5)
1.一种CHO细胞无血清传代培养基,其特征在于,所述无血清传代培养基包括氨基酸、维生素、脂质、无机盐、能量、微量元素以及其他添加物;其中:
氨基酸添加浓度范围为:L-精氨酸盐酸盐300-700mg/L、L-天冬酰胺500-800mg L、L-天冬氨酸200-500mg/L、L-半胱氨酸盐酸盐一水合物100-300mg/L、L-谷氨酸200-350mg/L、L-组氨酸盐酸盐一水合物200-350mg/L、L-异亮氨酸300-450mg/L、L-亮氨酸500-800mg/L、L-蛋氨酸100-250mg/L、L-赖氨酸盐酸盐400-550mg/L、L-脯氨酸300-600mg/L、L-缬氨酸350-550 mg/L、L-苯丙氨酸150-400mg/L、L-苏氨酸200-550mg/L、L-色氨酸200-400mg/L、L-胱氨酸100-200mg/L、L-丝氨酸500-900mg/L和L-酪氨酸二钠盐二水合物100-340mg/L;
维生素添加浓度范围为:维生素B2 1-2mg/L、维生素H 1-5mg/L、叶酸1-10mg/L、硫辛酸0.2-3mg/L、维生素B12 1-8mg/L、i-肌醇50-200mg/L、维生素B6 1-5mg/L、维生素B1 4-10mg/L、维生素C 10-30mg/L、D-泛酸钙5-20mg/L、烟酰胺1-10mg/L、氯化胆碱50-100mg/L;
无机盐及微量元素添加浓度范围为:MgSO4·7H2O 50-100mg/L、KCl 500-1000mg/L、硝酸铁九水合物0.1-0.5mg/L、二水氯化钙200-300mg/L、NaH2PO4 100-700mg/L、NaHCO3 1800-2500mg/L、ZnSO4 2-5mg/L、AlCl3·6H2O 0.0001-0.0005mg/L、NaVO3 0.001-0.005mg/L、Na2SeO3 0.007-0.020mg/L、CuSO4·5H2O 0.002-0.005mg/L、NaF 0.001-0.006mg/L、GeO20.002-0.005mg/L;
其他添加物的添加浓度范围为:胰岛素5-30mg/L、转铁蛋白5-30mg/L、白蛋白5-30mg/L、酵母水解物2000-7000mg/L或大豆蛋白胨3000-6000mg/L、乙醇胺2.5-15mg/L、精胺1-5mg/L、葡萄糖2000-6500mg/L、丙酮酸钠2000-6500mg/L、P-188 1000-2500mg/L、硫酸葡聚糖钠盐1000-3000mg/L和次黄嘌呤0.5-2mg/L。
2.根据权利要求1所述的无血清CHO细胞培养基,其特征在于,所述无血清传代培养基成分包含如下组成:
氨基酸添加浓度范围为:L-精氨酸盐酸盐400-600mg/L、L-天冬酰胺600-800mg L、L-天冬氨酸300-400mg/L、L-半胱氨酸盐酸盐一水合物200-300mg/L、L-谷氨酸300-350mg/L、L-组氨酸盐酸盐一水合物200-300mg/L、L-异亮氨酸300-400mg/L、L-亮氨酸500-600mg/L、L-蛋氨酸150-200mg/L、L-赖氨酸盐酸盐450-500mg/L、L-脯氨酸300-400mg/L、L-缬氨酸350-500mg/L、L-苯丙氨酸200-300mg/L、L-苏氨酸250-350mg/L、L-色氨酸200-300mg/L、L-胱氨酸100-200mg/L、L-丝氨酸700-900mg/L和L-酪氨酸二钠盐二水合物250-300mg/L;
维生素添加浓度范围为:维生素B2 1-2mg/L、维生素H 2-5mg/L、叶酸1-6mg/L、硫辛酸0.2-1mg/L、维生素B12 1-5mg/L、i-肌醇80-150mg/L、维生素B6 2-5mg/L、维生素B1 2-8mg/L、维生素C 10-20mg/L、D-泛酸钙5-15mg/L、烟酰胺5-10mg/L、氯化胆碱50-100mg/L;
无机盐及微量元素添加浓度范围为: MgSO4·7H2O 50-100mg/L、KCl 500-1000mg/L、硝酸铁九水合物0.1-0.5mg/L、二水氯化钙200-300mg/L、NaH2PO4 100-700mg/L、NaHCO3 1800-2500mg/L、ZnSO4 2-5mg/L、AlCl3·6H2O 0.0001-0.0005mg/L、NaVO3 0.001-0.005mg/L、Na2SeO3 0.007-0.020mg/L、CuSO4·5H2O 0.002-0.005mg/L、NaF 0.001-0.006mg/L、GeO20.002-0.005mg/L;
其他添加物的添加浓度范围为:胰岛素10-20mg/L、转铁蛋白10-20mg/L、白蛋白15-30mg/L、酵母水解物 2000-5000mg/L或大豆蛋白胨 3000-5000mg/L、乙醇胺2.5-15mg/L、精胺1-5mg/L、葡萄糖5000-6500mg/L、丙酮酸钠2000-6500mg/L、P-188 1000-2500mg/L、硫酸葡聚糖钠盐1000-3000mg/L、次黄嘌呤0.5-2mg/L。
3.权利要求1或2所述的适用于CHO-K1细胞无血清传代培养基的配置方法,其特征在于,按体积分别称量对应组分的克数溶解后,调节pH在7.0±0.2,加水定容后,使用氯化钠调节渗透压280±10 mOsm/kg,后使用0.22微摩尔滤膜无菌过滤,即得所述适用于CHO-K1细胞无血清传代培养基。
4.权利要求1或2所述CHO细胞传代培养基在CHO细胞培养中的用途。
5.根据权利要求4所述的应用,其特征在于,所述CHO细胞为CHO-K1。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310025615.9A CN115820542A (zh) | 2023-01-09 | 2023-01-09 | 一种cho细胞无血清传代培养基及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310025615.9A CN115820542A (zh) | 2023-01-09 | 2023-01-09 | 一种cho细胞无血清传代培养基及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115820542A true CN115820542A (zh) | 2023-03-21 |
Family
ID=85520418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310025615.9A Withdrawn CN115820542A (zh) | 2023-01-09 | 2023-01-09 | 一种cho细胞无血清传代培养基及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115820542A (zh) |
-
2023
- 2023-01-09 CN CN202310025615.9A patent/CN115820542A/zh not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105018416B (zh) | 一种悬浮培养bhk-21细胞的无血清无动物源培养基及其配制方法 | |
CN109337861B (zh) | 一种支持产物高表达的cho细胞无血清培养基 | |
CN106635953B (zh) | 无血清无蛋白细胞培养基 | |
Ham | Clonal growth of mammalian cells in a chemically defined, synthetic medium | |
CN100482783C (zh) | 一种用于Vero细胞的培养基及其培养方法 | |
CN107460159B (zh) | 无血清、无蛋白补料培养基及其制备方法和运用 | |
CN111996161B (zh) | 一种cho细胞无血清无蛋白培养基及其用途 | |
CN102827804B (zh) | 适用于Vero细胞微载体悬浮放大培养的培养基及方法 | |
CN101760442A (zh) | 适于mdck细胞大规模贴壁培养和单细胞悬浮培养的无血清培养基 | |
CN101418330B (zh) | 适于nso细胞大规模培养及抗体生产的无蛋白培养基 | |
CN100506977C (zh) | 一种中国仓鼠卵巢细胞扩增培养基及其用途 | |
NZ591651A (en) | High titer antibody production and culture media comprising glucose, soy or wheat hydrolsyate, amino acids, and other chemical compounds | |
CN106399224B (zh) | 无血清无蛋白细胞培养基 | |
CN101195817A (zh) | 一种杂交瘤细胞扩增培养基及其用途 | |
CN111019883A (zh) | Cho细胞悬浮培养的无血清无蛋白培养基及其用途 | |
CN111733126B (zh) | 一种Vero细胞无血清培养基及其用途 | |
CN111944741A (zh) | Mdck细胞系的悬浮培养驯化方法 | |
CN113930382A (zh) | 一种用于cho细胞表达抗狂犬病毒单克隆抗体的培养基 | |
CN112322577B (zh) | 一种用于cho细胞大规模培养的无血清培养基及应用 | |
CN110592000A (zh) | 一种支持bhk细胞高密度悬浮培养的无血清培养基 | |
CN112063578B (zh) | 适应全悬浮细胞培养的培养基及其制备方法和应用 | |
CN112442486B (zh) | 一种维持体外培养cho dg44细胞后期活率的培养基及其应用 | |
CN113913368A (zh) | 适合cho细胞大规模悬浮扩增培养的无血清培养基及其制备和应用 | |
CN115820542A (zh) | 一种cho细胞无血清传代培养基及其制备方法和应用 | |
CN105087460A (zh) | 一种st细胞培养基 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20230321 |